Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
160 mg furmonertinib first-line therapy for EGFR-mutant NSCLC with brain/leptomeningeal metastases
ChiCTR2500099395Phase 4Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of furmonertinib in non-small cell lung cancer (NSCLC), brain metastases and Carcinomatous Meningitis (CM), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Progression-free survival. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)brain metastasesCarcinomatous Meningitis (CM)
Beyond the preview
Go deeper on ChiCTR2500099395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099395.